-+ 0.00%
-+ 0.00%
-+ 0.00%

Disruptive Pharma Q3 loss after tax widens 74% to SEK 5.82 million

PUBT·11/12/2026 07:36:15
Disruptive Pharma Q3 loss after tax widens 74% to SEK 5.82 million
  • Disruptive Pharma’s third-quarter 2026 loss before and after tax widened 74% year over year to SEK 5.82 million.
  • Net sales rose 67% year over year to SEK 591,000 in the quarter.
  • Cash more than doubled year over year to SEK 33.92 million at September 30, 2026.
  • A September agreement to sell the GTX platform to an Aurelia Invest subsidiary will concentrate resources on Formulite’s commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disruptive Pharma AB (publ) published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.